| Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland. | |
| | |
MedLine Citation:
|
PMID: 16779715 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: The aim of this health economic modelling study was to investigate the effect of irbesartan combined with conventional antihypertensive medications compared to conventional antihypertensive therapy alone on the progression of nephropathy in patients with hypertension, type 2 diabetes and microalbuminuria in a Swiss setting. METHODS: In simulated patients with hypertension and type 2 diabetes, treatment of microalbuminuria with irbesartan 300 mg daily plus conventional antihypertensive medications was compared to a control regimen (conventional medications excluding angiotensin converting enzyme inhibitors, other angiotensin-2-receptor antagonist and dihydropyridine calcium channel blockers). Progression from microalbuminuria to nephropathy, doubling of serum creatinine, ESRD, and all-cause mortality was simulated over a 25-year time horizon using a published Markov model adapted to a Swiss setting. Transition probabilities were based on the Irbesartan in Reduction of Microalbuminuria-2 Study, Irbesartan in Diabetic Nephropathy Trial and other sources. Costs and clinical outcomes were discounted at 5% annually according to Swiss guidelines, and a third party payer perspective was taken. RESULTS: Treatment with irbesartan was projected to improve mean life expectancy by 0.57 years compared to conventional antihypertension treatment (undiscounted 1.22 years). Irbesartan treatment was associated with cost savings of CHF 21,488 per patient over the 25-year time horizon. Sensitivity analysis showed that irbesartan therapy remained dominant to conventional antihypertension treatment over a range of plausible assumptions. CONCLUSIONS: Addition of irbesartan to conventional antihypertension therapy was projected to improve life expectancy and reduce costs in hypertensive patients with type 2 diabetes and microalbuminuria in a Swiss setting. |
| | |
Authors:
|
Andrew J Palmer; Stéphane Roze; William J Valentine; Joshua A Ray; Andreas Frei; Michel Burnier; Bernhard Hess; Giatgen A Spinas; Michael Brändle |
Related Documents
:
|
15488165 - Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes. 20854235 - Cost-effectiveness of lowering blood pressure with a fixed combination of perindopril a... 20213375 - Impact of reimbursement changes on statin use among patients with diabetes in austria. 20496315 - Excess health care costs of obesity in adults with diabetes mellitus: a claims data ana... 11762515 - Physiological influences on off-finger glucose testing. 14755135 - Inhibition of ras-gtpase improves diabetes-induced abnormal vascular reactivity in the ... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Swiss medical weekly Volume: 136 ISSN: 1424-7860 ISO Abbreviation: Swiss Med Wkly Publication Date: 2006 May |
Date Detail:
|
Created Date: 2006-06-16 Completed Date: 2006-10-27 Revised Date: 2011-02-15 |
Medline Journal Info:
|
Nlm Unique ID: 100970884 Medline TA: Swiss Med Wkly Country: Switzerland |
Other Details:
|
Languages: eng Pagination: 346-52 Citation Subset: IM |
Affiliation:
|
Center for Outcomes Research (CORE), Binningen/Basel, Switzerland. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Albuminuria
/
drug therapy*,
economics Angiotensin II Type 1 Receptor Blockers / administration & dosage, economics, therapeutic use* Antihypertensive Agents / administration & dosage, economics, therapeutic use* Biphenyl Compounds / administration & dosage, economics, therapeutic use* Cohort Studies Cost Savings Creatinine / blood Diabetes Mellitus, Type 2 / drug therapy*, economics Diabetic Nephropathies / drug therapy*, economics Follow-Up Studies Humans Hypertension / complications, drug therapy*, economics Life Expectancy Markov Chains Practice Guidelines as Topic Switzerland Tetrazoles / administration & dosage, economics, therapeutic use* Time Factors Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin II Type 1 Receptor Blockers; 0/Antihypertensive Agents; 0/Biphenyl Compounds; 0/Tetrazoles; 138402-11-6/irbesartan; 60-27-5/Creatinine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Utilisation of inpatient psychiatric services by people with illicit substance abuse in Switzerland.
Next Document: Repeated laser-assisted high-flow bypass for recurrent giant intracranial aneurysm.